valdecoxib

Known as: 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide, valdecoxib [Chemical/Ingredient] 
A sulfonamide derivative and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Valdecoxib… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Clinical trial data have prompted questions about the degree to which patients and their physicians should consider an increased… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Valdecoxib and its intravenous prodrug parecoxib are reported to increase thromboembolic risk after coronary artery… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
Valdecoxib is a new non-steroidal antiinflammatory drug, mainly used for osteoarthritis, rheumatoid arthritis, and dysmenorrhea… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Selective inhibitors of cyclooxygenase (COX)-2 1 depress prostacyclin (PGI2) but not COX-1–derived thromboxane A2. The effects of… (More)
Is this relevant?
2005
2005
AGEP (acute generalized exanthematous pustulosis) is a relatively rare exfoliative skin syndrome consisting of generalized… (More)
Is this relevant?
2005
2005
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Formulation of poorly water-soluble drugs in the most stable dosage form for oral delivery perhaps presents the greatest… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE Inhibition of cyclooxygenase 2 provides analgesia in ambulatory patients. We prospectively evaluated the safety and… (More)
Is this relevant?
2002
2002
The platelet effects of a supratherapeutic dose of the new cyclooxygenase (COX)-2 specific inhibitor, valdecoxib (40 mg twice a… (More)
Is this relevant?